This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Believe Revolution Medicines (RVMD) Could Rally 90.58%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 90.6% in Revolution Medicines (RVMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Revolution Medicines (RVMD) Have the Potential to Rally 74.05% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Revolution Medicines (RVMD) points to a 74.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Keros Therapeutics (KROS) Soars 5.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Keros Therapeutics (KROS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Down -7.83% in 4 Weeks, Here's Why Revolution Medicines (RVMD) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Revolution Medicines (RVMD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Revolution Medicines (RVMD) Loses -7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
Revolution Medicines (RVMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Is John Hancock Multifactor Small Cap ETF (JHSC) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for JHSC
Should John Hancock Multifactor Small Cap ETF (JHSC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JHSC
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
by Zacks Equity Research
Revolution Medicines (RVMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sage Therapeutics (SAGE) delivered earnings and revenue surprises of -10.43% and 28.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -32.56% and 87.63%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 27.5% Upside in Revolution Medicines, Inc. (RVMD): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Revolution Medicines, Inc. (RVMD) points to a 27.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 1.98% and 100%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurinia (AUPH) delivered earnings and revenue surprises of 47.06% and 41.94%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines, Inc. (RVMD) Soars 23.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Revolution Medicines, Inc. (RVMD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of -10.84% and 4.40%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Revolution Medicines, Inc. (RVMD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 14.29% and 68.36%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Crinetics Pharmaceuticals, Inc. (CRNX) delivered earnings and revenue surprises of -3.66% and 325.24%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
AcelRx Pharmaceuticals (ACRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
AcelRx Pharmaceuticals (ACRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Revolution Medicines, Inc. (RVMD) Could Surge 27.24%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 27.2% in Revolution Medicines, Inc. (RVMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Revolution Medicines, Inc. (RVMD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Revolution Medicines, Inc. (RVMD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 25% and 127.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Are You Looking for a Top Momentum Pick? Why Revolution Medicines, Inc. (RVMD) is a Great Choice
by Zacks Equity Research
Does Revolution Medicines, Inc. (RVMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Strength Seen in Revolution Medicines, Inc. (RVMD): Can Its 15.9% Jump Turn into More Strength?
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Revolution Medicines, Inc. (RVMD) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Revolution Medicines, Inc. (RVMD) delivered earnings and revenue surprises of 0% and 60.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?